1 trials tracked · 1 active · last refreshed 2026-08-10
ANPD001 (Aspen Neuroscience) is an autologous cell therapy — like bemdaneprocel, it replaces lost dopamine neurons via implant, but instead of a standardized product made from donor cells, it's grown from each patient's own skin cells, reprogrammed into stem cells and then into dopamine neurons specific to that patient. The appeal is avoiding any immune rejection risk that a donor-cell product carries; the tradeoff is a more complex, personalized manufacturing process for every patient treated.
Its only tracked trial is an early Phase 1/2a safety study, enrolling by invitation rather than open recruitment — an earlier-stage, smaller program than bemdaneprocel's, both pursuing the same regenerative concept via different manufacturing approaches.
Click a row for what it's testing, where, and how many participants.
| NCT ID | Title | Phase | Status | Started | |
|---|---|---|---|---|---|
| ▸ | NCT06344026 | Phase 1/2a Study of ANPD001 in Parkinson Disease | Phase I | Enrolling by invitation | 2024-01-23 |
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells. Enrollment 9 (estimated) Sites 9 across 1 country Countries United States Sponsor Aspen Neuroscience Primary outcome: Incidence and severity of treatment emergent adverse events (Safety and Tolerability) | |||||
This page is regenerated from ClinicalTrials.gov data and summarized once per refresh — nothing here is generated live when you visit. For informational purposes only; not medical advice.